• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.

作者信息

Lee Grace A, Rao Madhu N, Grunfeld Carl

出版信息

Curr Infect Dis Rep. 2004 Dec;6(6):471-482. doi: 10.1007/s11908-004-0067-5.

DOI:10.1007/s11908-004-0067-5
PMID:15538985
Abstract

Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.

摘要

相似文献

1
The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.
Curr Infect Dis Rep. 2004 Dec;6(6):471-482. doi: 10.1007/s11908-004-0067-5.
2
The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.人类免疫缺陷病毒蛋白酶抑制剂对碳水化合物和脂质代谢的影响。
Curr HIV/AIDS Rep. 2005 Feb;2(1):39-50. doi: 10.1007/s11904-996-0008-z.
3
HIV protease inhibitors stimulate hepatic triglyceride synthesis.HIV蛋白酶抑制剂会刺激肝脏甘油三酯的合成。
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2625-9. doi: 10.1161/01.atv.20.12.2625.
4
HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.
Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G1071-80. doi: 10.1152/ajpgi.00182.2006. Epub 2006 Jul 20.
5
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.HIV蛋白酶抑制剂在体外可阻断脂肪生成并增加脂肪分解。
Antiviral Res. 2000 Aug;47(2):121-9. doi: 10.1016/s0166-3542(00)00102-9.
6
Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.对脂肪细胞脂质代谢和存活有不良影响的抗逆转录病毒药物在体外会改变促炎细胞因子和脂联素的表达及分泌。
Antivir Ther. 2004 Dec;9(6):911-20.
7
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.接受蛋白酶抑制剂治疗的HIV感染者的致动脉粥样硬化性血脂异常。瑞士HIV队列研究。
Circulation. 1999 Aug 17;100(7):700-5. doi: 10.1161/01.cir.100.7.700.
8
Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases.1型人类免疫缺陷病毒蛋白酶抑制剂与肿瘤坏死因子α的协同抗脂肪生成作用:抑制细胞外基质降解蛋白酶介导的细胞外胰岛素作用。
AIDS Res Hum Retroviruses. 2001 Nov 20;17(17):1569-84. doi: 10.1089/088922201753341988.
9
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.利托那韦增强达芦那韦与利托那韦增强阿扎那韦对 HIV 阴性健康志愿者血脂和血糖参数的影响。
HIV Med. 2009 May;10(5):318-27. doi: 10.1111/j.1468-1293.2008.00690.x. Epub 2009 Feb 5.
10
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.用于治疗HIV-1感染患者的蛋白酶抑制剂联合用药:药代动力学及临床经验综述
Antivir Ther. 2001 Dec;6(4):201-29.

引用本文的文献

1
Association of HIV-1 Infection and Antiretroviral Therapy With Type 2 Diabetes in the Hispanic Population of the Rio Grande Valley, Texas, USA.美国得克萨斯州里奥格兰德河谷西班牙裔人群中HIV-1感染及抗逆转录病毒疗法与2型糖尿病的关联
Front Med (Lausanne). 2021 Jul 5;8:676979. doi: 10.3389/fmed.2021.676979. eCollection 2021.
2
Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity.高血糖会加剧抗逆转录病毒药物联合使用引起的血脑屏障内皮毒性。
Neurotoxicology. 2016 Sep;56:1-6. doi: 10.1016/j.neuro.2016.06.011. Epub 2016 Jun 23.
3
Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors.

本文引用的文献

1
Indinavir increases glucose production in healthy HIV-negative men.茚地那韦可增加健康的HIV阴性男性的葡萄糖生成。
AIDS. 2004 Sep 3;18(13):1852-4. doi: 10.1097/00002030-200409030-00017.
2
Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy.
AIDS. 2004 Aug 20;18(12):1742-4. doi: 10.1097/01.aids.0000131387.38103.7e.
3
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.每日一次的阿扎那韦与依非韦伦分别联合固定剂量的齐多夫定和拉米夫定作为HIV感染患者初始治疗的比较。
高血糖通过下调维生素D受体加重HIV相关性肾病中的肾细胞损伤。
Cell Signal. 2015 Mar;27(3):460-9. doi: 10.1016/j.cellsig.2014.12.011. Epub 2014 Dec 24.
4
Diabetes and HIV.糖尿病与艾滋病病毒。
Clin Med (Lond). 2014 Dec;14(6):667-9. doi: 10.7861/clinmedicine.14-6-667.
5
Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction.接受治疗的HIV阳性个体的血浆脂质组学分析及其对心血管疾病风险预测的意义。
PLoS One. 2014 Apr 14;9(4):e94810. doi: 10.1371/journal.pone.0094810. eCollection 2014.
6
South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.南亚人类免疫缺陷病毒/获得性免疫缺陷综合征患者糖尿病合理管理共识指南
Indian J Endocrinol Metab. 2011 Oct;15(4):242-50. doi: 10.4103/2230-8210.85573.
7
Understanding diabetes in patients with HIV/AIDS.了解 HIV/AIDS 患者中的糖尿病。
Diabetol Metab Syndr. 2011 Jan 14;3(1):2. doi: 10.1186/1758-5996-3-2.
8
Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.抗逆转录病毒药物通过氧化应激依赖途径诱导血管内皮功能障碍,并促进内膜增生。
Toxicol Sci. 2010 Oct;117(2):524-36. doi: 10.1093/toxsci/kfq213. Epub 2010 Jul 9.
9
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.蛋白酶抑制剂在HIV相关脂肪代谢障碍发病机制中的作用:细胞机制及临床意义
Toxicol Pathol. 2009 Jan;37(1):65-77. doi: 10.1177/0192623308327119. Epub 2009 Jan 26.
10
The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.蛋白酶抑制剂在HIV相关胰岛素抵抗发病机制中的作用:细胞机制及临床意义
Curr HIV/AIDS Rep. 2007 Aug;4(3):126-34. doi: 10.1007/s11904-007-0019-4.
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003.
4
Direct interference of HIV protease inhibitors with pancreatic beta-cell function.HIV蛋白酶抑制剂对胰腺β细胞功能的直接干扰。
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):583-90. doi: 10.1007/s00210-004-0933-6. Epub 2004 May 7.
5
Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells.脂肪营养不良的HIV感染患者的胰岛素分泌与高水平的非葡萄糖促分泌剂及β细胞胰岛素抵抗有关。
Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E677-85. doi: 10.1152/ajpendo.00009.2004. Epub 2004 May 18.
6
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.罗格列酮对HIV脂肪代谢障碍的代谢影响:一项随机对照试验。
Ann Intern Med. 2004 May 18;140(10):786-94. doi: 10.7326/0003-4819-140-10-200405180-00008.
7
HIV protease inhibitors increase adiponectin levels in HIV-negative men.HIV蛋白酶抑制剂可提高HIV阴性男性体内脂联素水平。
J Acquir Immune Defic Syndr. 2004 May 1;36(1):645-7. doi: 10.1097/00126334-200405010-00017.
8
Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients.运动训练和二甲双胍对HIV感染患者身体成分和心血管指标的影响。
AIDS. 2004 Feb 20;18(3):465-73. doi: 10.1097/00002030-200402200-00013.
9
The metabolic effects of lopinavir/ritonavir in HIV-negative men.洛匹那韦/利托那韦对HIV阴性男性的代谢影响。
AIDS. 2004 Mar 5;18(4):641-9. doi: 10.1097/00002030-200403050-00008.
10
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):324-6. doi: 10.1097/00126334-200403010-00017.